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Patient-reported outcome measures (PROMs), defined as
‘a measurement of any aspect of a patient’s health status that
comes directly from the patient’ (Sloan et al, 2007), are
increasingly being adopted into oncology research and clinical
practice. In research, traditional outcomes, such as tumour
response and mortality, are being supplemented with subjective
evaluations of quality of life, satisfaction with care, psychological
distress and symptom control. In clinical care, routine screening
using PROMs is useful to identify clinical issues, focus discussions,
identify problems, and track issues over time. Because of the
perceived advantages in efficiency and feasibility, there is
growing interest in short (5–20 item) or ultra-short (1–4 item)
measures (Vodermaier et al, 2009). But how short is too short? Is
there a point at which these measures become too brief to be
meaningful?
In this issue of the British Journal of Cancer, Phillips et al (2010)
report on a three-item patient-reported clinic satisfaction measure
for young adults. Consecutive adult outpatients who were long-
term survivors of childhood cancer completed a 16-item satisfac-
tion with communication questionnaire; the data were used to
develop a 3-item questionnaire, which was subsequently validated
against the 16-item measure using data from a second study. The
brief measure was highly correlated with the original longer
measure in both the derivation and validation data sets, and had a
fair capacity to discriminate between satisfaction and dissatisfac-
tion using a specified cutoff point.
As Phillips et al point out, short questionnaires have obvious
advantages. They take less time to complete, are less burdensome
for patients, and have higher rates of completion and return.
Missing data are a common problem in trials using PROMs and
can lead to loss of power and biased results (Huntington and
Dueck, 2005). Although there are various strategies to handle
missing data, the best solution is prevention, including minimising
patient burden with brief measures. In clinical practice, short
PROMs interfere less with the efficient running of the clinic,
particularly if they are to be completed before the appointment
(such as for screening measures). In addition, they are less
costly, because fewer personnel are necessary for administration,
data entry and scoring. The advantages of short measures are
perhaps best illustrated by pragmatic studies of acceptability. In a
UK study assessing acceptability of common distress screening
methods, only 1% of cancer clinicians indicated that they would
be prepared to use a measure that was longer than 10 items
(Mitchell et al, 2008).
Despite these advantages, there are also drawbacks to shorter
questionnaires. The main doubt, particularly with ultra-short
measures, is concerning their reliability and validity. In oncology,
this issue has been investigated most thoroughly regarding
measures of psychological distress, particularly depression.
Mitchell (2007) reviewed 38 studies examining ultra-short PROMs
for distress, and found that these tools were very good at excluding
possible cases of depression (sensitivity 78%, negative predictive
value 93%), but were poor at ruling in a suspected diagnosis
(specificity 67%, positive predictive value 34%). This raises
questions about what to do with the large numbers of patients
who have a positive screen. Options include referring these
patients directly to a professional who can diagnose depression, or
administering a longer, more specific questionnaire; both of these
options are again costly and/or burdensome, albeit for a smaller
number of patients. In research situations, the lack of specificity of
ultra-short distress measures is of even greater concern, and they
are therefore not recommended for use in trials or other research
studies (Vodermaier et al, 2009).
Outcomes of PROMs can range from individual physical
symptoms to complex end points, such as quality of life. Ultra-
short measures are likely most useful in situations, in which
a clear single question is asked regarding a discrete outcome in a
single domain. The numeric rating scale for pain is one example, in
which a single-item scale has demonstrated validity and reliability,
and is suitable for use in research settings (Breivik et al,
2008). Quality of life has physical, psychological, social and
functional domains; although ultra-short and single-item measures
have been validated, they are less reliable (stable) than
multi-domain questionnaires, and their ambiguity limits their
value as screening aids (Sloan et al, 2002). The more vague a
single question or series of questions, the less likely it is that all
patients will interpret the question in the same way, and the
less likely it is that this will change following an intervention,
because many aspects other than the intervention may have an
influence. For example, in a study measuring the efficacy of a
palliative care clinic on symptom control, there was significant
improvement in 10 individual symptoms after the intervention,
but a single-item measure of well-being did not change (Follwell
et al, 2009).
The validation of ultra-short measures for depression has the
advantage of an established ‘gold standard’ against which
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according to the aspect of satisfaction that is being measured. The
measure developed by Phillips et al measures satisfaction with
communication, and was validated by comparing the 3-item
measure to the larger 16-item measure within which it was
situated. As the authors acknowledge, the three questions may be
answered differently if administered independently; comparison of
the three-item measure against other measures of satisfaction and
related constructs is needed for further validation.
Ultra-short measures may be developed de novo,o rb y
eliminating all but a few items from a longer questionnaire. The
roots of the 3-item measure developed by Phillips et al can be
traced to a 55-item patient satisfaction questionnaire developed by
Ware et al in the 1980s (Ware et al, 1983). This measure was
shortened to a 28-item measure containing items specifically
related to communication, which was then pilot tested and reduced
to the 17-item patient satisfaction with communication ques-
tionnaire (Shilling et al, 2003), which was further reduced to 16
items (Absolom et al, 2006) and finally to 3. At each step of item
reduction, information is lost, unless items are redundant, and it
needs to be kept in mind that the questionnaire has the capacity to
assess only the questions that are being asked. For example, the
brief PROM developed by Phillips et al assesses understanding by
asking whether medical terms were used that were not understood;
however, this question may pertain more to physicians than to
nurses or other staff, and a clinician may be difficult to understand
without using medical terminology.
Ultimately, the choice of using an ultra-short measure or a
longer one needs to take into account the advantages or
disadvantages in the particular setting and circumstance that the
measure will be used. Ultra-short measures are appropriate as
research outcomes, particularly as secondary end points, as long as
a discrete single domain is being measured. They also have a place
as clinical screening measures, in which they have an advantage
over longer measures in terms of feasibility and cost. However,
there needs to be a realistic interpretation of the results, and a
preestablished, concrete plan of what will be done with them. Little
good comes from identifying a patient who may have depression
or who may be dissatisfied with care, if there is no follow-up on an
individual or an institutional basis.
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